Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SNPX

Synaptogenix Inc

Last Close
Apr 26 • 04:00PM ET
4.53
Dollar change
+0.12
Percentage change
2.65 		%
Held by: VXF
Index- P/E- EPS (ttm)-43.39 Insider Own3.24% Shs Outstand1.09M Perf Week4.62%
Market Cap4.94M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.05M Perf Month-4.88%
Income-13.78M PEG- EPS next Q- Inst Own5.03% Short Float3.21% Perf Quarter-9.22%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio0.68 Perf Half Y-35.22%
Book/sh25.27 P/B0.18 EPS next Y- ROA-17.32% Short Interest0.03M Perf Year-79.87%
Cash/sh27.61 P/C0.16 EPS next 5Y- ROE-21.17% 52W Range3.53 - 47.00 Perf YTD-33.36%
Dividend Est.- P/FCF- EPS past 5Y8.59% ROI-56.59% 52W High-90.36% Beta1.55
Dividend TTM- Quick Ratio7.14 Sales past 5Y0.00% Gross Margin- 52W Low28.42% ATR (14)0.50
Dividend Ex-Date- Current Ratio7.14 EPS Y/Y TTM-113.06% Oper. Margin0.00% RSI (14)47.27 Volatility6.00% 12.59%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price350.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-108.10% Payout- Rel Volume0.14 Prev Close4.41
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume49.66K Price4.53
SMA20-2.80% SMA50-4.91% SMA200-46.08% Trades Volume6,924 Change2.65%
Apr-24-24 09:15AM
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
(PR Newswire)
Apr-09-24 09:15AM
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics
(PR Newswire) -8.35%
Apr-03-24 08:00AM
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
(PR Newswire)
Dec-19-23 09:00AM
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders
(PR Newswire) +5.45%
Dec-06-23 09:00AM
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
(PR Newswire)
09:00AM Loading…
Nov-02-23 09:00AM
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology
(PR Newswire)
Sep-26-23 09:00AM
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease
(PR Newswire) +5.67%
Sep-07-23 09:00AM
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study
(PR Newswire) -12.23%
Jul-19-23 09:00AM
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis
(PR Newswire)
Jul-13-23 09:00AM
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience
(PR Newswire) +20.79%
Mar-07-23 09:00AM
Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities
(PR Newswire)
Dec-16-22 09:00AM
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease
(PR Newswire) -74.63%
Nov-18-22 09:00AM
Synaptogenix Announces $15 Million Private Placement with Existing Investors
(PR Newswire) +12.72%
Oct-19-22 09:00AM
Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022
(PR Newswire)
Sep-28-22 11:50AM
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results
(PR Newswire)
09:00AM Loading…
Aug-12-22 09:00AM
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network
(PR Newswire) +5.10%
Jul-26-22 09:15AM
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data
(PR Newswire) +6.37%
Jul-21-22 09:15AM
Synaptogenix Announces Corporate Update Conference Call
(PR Newswire)
Jul-20-22 09:15AM
Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data
(PR Newswire) +5.81%
May-17-22 09:15AM
Synaptogenix to Present at the Cell Symposium
(PR Newswire) +10.97%
Apr-19-22 09:15AM
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial
(PR Newswire) -5.69%
Apr-05-22 09:15AM
New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease
(PR Newswire)
Mar-29-22 09:15AM
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit
(PR Newswire)
Mar-22-22 09:15AM
Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum
(PR Newswire)
Mar-15-22 09:15AM
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
(PR Newswire)
Feb-23-22 09:15AM
Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis
(PR Newswire)
Feb-07-22 09:38AM
Orion Capital Management LLC Buys Qualcomm Inc, Distillate U.S. ...
(GuruFocus.com) -5.88%
Feb-01-22 09:15AM
Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients
(PR Newswire) +29.36%
Dec-06-21 11:58AM
We're Hopeful That Synaptogenix (NASDAQ:SNPX) Will Use Its Cash Wisely
(Simply Wall St.)
Sep-28-21 09:00AM
Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference
(PR Newswire)
09:00AM Loading…
Sep-10-21 09:00AM
Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference
(PR Newswire)
Aug-05-21 10:00AM
Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome
(PR Newswire) -6.18%
Jul-26-21 09:15AM
Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021
(PR Newswire) -19.09%
Jul-21-21 09:00AM
Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings
(PR Newswire) +19.86%
Jul-14-21 09:00AM
Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline
(PR Newswire) +9.74%
Jul-07-21 09:00AM
Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease
(PR Newswire) -13.16%
Jun-24-21 09:00AM
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network
(PR Newswire)
Jun-14-21 09:00AM
Synaptogenix Announces $12.5 Million Private Placement
(PR Newswire)
Jun-09-21 09:00AM
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update
(PR Newswire)
05:38AM
Is Synaptogenix (NASDAQ:SNPX) In A Good Position To Deliver On Growth Plans?
(Simply Wall St.)
May-19-21 09:00AM
Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market
(PR Newswire)
May-10-21 09:00AM
Synaptogenix, Inc: Invitation to the Benzinga Global Small Cap Conference
(Newsfile) -12.50%
Apr-26-21 09:00AM
Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum
(PR Newswire) +7.60%
Apr-01-21 09:00AM
Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update
(PR Newswire)
Mar-05-21 09:00AM
Synaptogenix to Present at the H.C. Wainwright Global Life Sciences Conference
(PR Newswire) -8.16%
Feb-25-21 09:12AM
Synaptogenix to Present at Upcoming Scientific Industry Conferences
(PR Newswire)
Feb-12-21 09:00AM
Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference
(PR Newswire)
Feb-09-21 09:00AM
Synaptogenix Files Application to List on the Nasdaq Stock Market
(PR Newswire) +20.83%
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer's disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

XWEL

XWELL Inc

Last Close
Apr 26 • 04:00PM ET
1.80
Dollar change
0.00
Percentage change
0.00 		%
XWEL XWELL Inc daily Stock Chart
Held by: VXF VTI
Index- P/E- EPS (ttm)-6.65 Insider Own2.96% Shs Outstand4.18M Perf Week30.43%
Market Cap7.52M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.06M Perf Month5.88%
Income-27.74M PEG- EPS next Q- Inst Own8.64% Short Float1.62% Perf Quarter21.62%
Sales30.11M P/S0.25 EPS this Y- Inst Trans- Short Ratio5.15 Perf Half Y0.56%
Book/sh3.11 P/B0.58 EPS next Y- ROA-50.71% Short Interest0.07M Perf Year-67.11%
Cash/sh5.51 P/C0.33 EPS next 5Y20.00% ROE-104.83% 52W Range1.26 - 6.40 Perf YTD3.45%
Dividend Est.- P/FCF- EPS past 5Y66.28% ROI-127.87% 52W High-71.88% Beta2.39
Dividend TTM- Quick Ratio2.75 Sales past 5Y124.62% Gross Margin5.37% 52W Low42.86% ATR (14)0.13
Dividend Ex-Date- Current Ratio2.85 EPS Y/Y TTM8.37% Oper. Margin-63.65% RSI (14)63.11 Volatility11.33% 7.96%
Employees337 Debt/Eq0.85 Sales Y/Y TTM-46.18% Profit Margin-92.14% Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq0.67 EPS Q/Q51.28% Payout- Rel Volume0.63 Prev Close1.80
Sales Surprise1.23% EPS Surprise0.00% Sales Q/Q-2.05% EarningsApr 16 AMC Avg Volume12.75K Price1.80
SMA2019.57% SMA501.11% SMA200-28.76% Trades Volume8,021 Change0.00%
Apr-19-24 09:00AM
XWELL Inc (XWEL) Q4 2023 Earnings Call Transcript Highlights: Strategic Expansions and Cost ...
(GuruFocus.com)
Apr-17-24 08:48AM
XWELL, Inc. (NASDAQ:XWEL) Q4 2023 Earnings Call Transcript
(Insider Monkey)
Apr-16-24 11:52PM
XWEL Stock Earnings: XWELL Misses EPS, Misses Revenue for Q4 2023
(InvestorPlace)
04:30PM
XWELL, Inc. Reports Fiscal Year 2023 Results
(GlobeNewswire)
08:00AM
XWELL, Inc. to Report Fiscal Year 2023 Financial Results on Tuesday, April 16, 2024
(GlobeNewswire)
04:30PM Loading…
Apr-01-24 04:30PM
XWELL, Inc. Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K
(GlobeNewswire)
Mar-12-24 07:01AM
CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago
(PR Newswire)
Feb-14-24 08:00AM
XWELL Advances Expansion Plan Outside the Airport with Three New Naples Wax and Skin Care Locations
(GlobeNewswire) +11.18%
Jan-04-24 08:00AM
XWELL Announces Plans to Open an XpresSpa in THE PENN DISTRICT
(GlobeNewswire)
Dec-15-23 04:15PM
XWELL Appoints Veteran Consumer & Wellness Entrepreneur Ga lle Wizenberg to its Board of Directors
(GlobeNewswire)
Dec-11-23 08:00AM
XpresSpa Introduces Clockwork Robotic Manicures at Harry Reid International Airport in Las Vegas
(GlobeNewswire)
Nov-15-23 08:00AM
XWELL Opens New XpresSpa Location in Abu Dhabi International Airport
(GlobeNewswire)
Nov-14-23 04:30PM
XWELL, Inc. Reports Third Quarter 2023 Results
(GlobeNewswire) +5.93%
Nov-06-23 07:06AM
US CDC to expand surveillance of travelers for respiratory viruses
(Reuters)
07:00AM
Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens
(PR Newswire)
08:00AM Loading…
Oct-11-23 08:00AM
XWELL Unveils New Corporate Identity and Enhanced Website for its Leading Airport Spa Brand, Xpres Spa
(GlobeNewswire) -6.47%
Oct-09-23 08:00AM
XWELL's CEO Scott Milford Discusses Strategic Growth Plans During Recent Investor Fireside Chat
(GlobeNewswire)
Oct-02-23 08:00AM
XWELL Celebrates Breast Cancer Awareness Month with Philanthropic Nail Care Program
(GlobeNewswire)
Sep-28-23 09:00AM
XWELL s CEO Scheduled to Present at Upcoming Investor Fireside Chat on October 4, 2023
(GlobeNewswire) -10.77%
Sep-27-23 08:00AM
XWELL, Inc. Announces 1-for-20 Reverse Stock Split
(GlobeNewswire) -25.40%
Sep-19-23 08:00AM
XWELL Introduces New Stretch Service at XpresSpa
(GlobeNewswire)
Sep-12-23 04:30PM
XWELL Grows Footprint Outside the Airport with Acquisition of Naples Wax Center
(GlobeNewswire) +8.43%
Aug-19-23 08:02AM
XWELL, Inc. (NASDAQ:XWEL) Q2 2023 Earnings Call Transcript
(Insider Monkey)
Aug-17-23 08:08AM
XWELL Extends Collaboration with Centers for Disease Control and Preventions Traveler-Based Genomic Surveillance Program
(GlobeNewswire)
Aug-15-23 06:23AM
Q2 2023 XWELL Inc Earnings Call
(Thomson Reuters StreetEvents) -10.87%
Aug-14-23 04:30PM
XWELL, Inc. Reports Second Quarter 2023 Results
(GlobeNewswire)
Aug-07-23 04:30PM
XWELL, Inc. to Announce Second Quarter 2023 Financial Results on Monday, August 14
(GlobeNewswire)
Jul-20-23 08:00AM
XpresSpa Debuts Clockwork Robotic Manicures at Miami International Airport
(GlobeNewswire)
Jul-18-23 04:15PM
XWELL Unveils XWELL Rewards Loyalty Program
(GlobeNewswire) +18.32%
Jul-14-23 11:22AM
Here's Why We're A Bit Worried About XWELL's (NASDAQ:XWEL) Cash Burn Situation
(Simply Wall St.) -5.56%
08:00AM Loading…
Jul-13-23 08:00AM
XWELL, Inc. Appoints Suzanne Scrabis as Chief Financial Officer
(GlobeNewswire) +12.50%
May-16-23 05:54AM
Q1 2023 XWELL Inc Earnings Call
(Thomson Reuters StreetEvents)
May-15-23 04:30PM
XWELL, Inc. Reports First Quarter 2023 Results
(GlobeNewswire)
May-11-23 12:39PM
Hey Redditors! Its Time to Dump MULN Stock Before It Falls Below $1.
(InvestorPlace)
08:00AM
XWELL, Inc. to Announce First Quarter 2023 Financial Results on Monday, May 15
(GlobeNewswire)
May-04-23 08:00AM
XWELL, Inc. Names Valerie Lightfoot Chief Financial Officer
(GlobeNewswire) +9.01%
May-03-23 08:00AM
XWELL Unveils Automated Massage Chairs at XpresSpa Locations Across the U.S.
(GlobeNewswire)
Apr-27-23 04:15PM
XWELL, Inc. Granted 180-Day Extension by NASDAQ to Regain Compliance with Minimum Bid Price Rule
(GlobeNewswire) -10.45%
Apr-19-23 03:54PM
Revenues Working Against XWELL, Inc.'s (NASDAQ:XWEL) Share Price
(Simply Wall St.)
Apr-18-23 06:35AM
Q4 2022 XWELL Inc Earnings Call
(Thomson Reuters StreetEvents) -7.93%
Apr-17-23 04:15PM
XWELL, Inc. Reports Fiscal Year 2022 Results
(GlobeNewswire) +5.22%
Apr-14-23 05:05PM
XWELL, Inc. to Announce 2022 Financial Results on Monday April 17
(GlobeNewswire)
Mar-30-23 04:30PM
XWELL Announces Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K And Provides Preliminary FY2022 Operating Update
(GlobeNewswire)
Mar-22-23 08:00AM
First Robot Manicure Unveiled at XpresSpa at John F. Kennedy International Airport
(GlobeNewswire)
Jan-31-23 08:00AM
XWELL to Participate in Water Tower Fireside Chat Series
(GlobeNewswire)
Jan-17-23 08:00AM
Ginkgo Bioworks and XpresCheck Expand CDCs Traveler-Based Genomic Surveillance Program to Detect Influenza Variants
(GlobeNewswire)
Dec-20-22 09:11AM
12 Penny Stocks With Biggest Upside
(Insider Monkey)
Dec-12-22 08:00AM
XWELL Chief Executive Officer Issues Letter to Shareholders Regarding the Companys Operating Strategy
(GlobeNewswire)
Dec-05-22 08:00AM
XWELL to Bring State of the Art Technology to XpresSpa and Treat Locations in Partnership with HydroMassage® and Human Touch®
(GlobeNewswire)
Nov-16-22 05:20AM
XWELL Third Quarter 2022 Earnings: US$0.076 loss per share (vs US$0.053 profit in 3Q 2021)
(Simply Wall St.) -9.60%
Nov-10-22 04:00PM
XWELL, Inc. Reports Third Quarter 2022 Results
(GlobeNewswire)
Nov-09-22 08:00AM
XWELL Increases International Footprint with Five New XpresSpa Locations at Istanbul International Airport
(GlobeNewswire) -5.22%
Nov-07-22 08:00AM
XWELL to Bring Robotic Manicures to US Airports Through New Partnership with Clockwork
(GlobeNewswire) -6.61%
Nov-03-22 06:00PM
XWELL, Inc. to Announce Third Quarter 2022 Financial Results on Thursday, November 10
(GlobeNewswire)
Nov-02-22 04:00PM
XWELL Celebrates Opening of New Treat Location at Salt Lake City International Airport
(GlobeNewswire)
XWELL, Inc. provides global travel health and wellness services. It operates through the following segments: XpresSpa, XpresTest, Naples Wax Center, Treat, and Corporate & Other. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. The Naples Wax Center segment is focused on the products and service offerings from face and body waxing to a range of skincare and cosmetic products. The Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers. The company was founded by Jonathan Medved and David Goldfarb on January 9, 2006 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WEINSTEIN ROBERTDirectorMay 30 '23Buy0.2525,0006,175156,485May 31 08:32 AM
WEINSTEIN ROBERTDirectorMay 26 '23Buy0.2525,0006,250131,485May 30 08:34 AM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.